What Rigel Pharmaceuticals Inc does.

We are a biotechnology company dedicated to developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. We focus on products that address signaling pathways that are critical to disease mechanisms.

TAVALISSE ® (fostamatinib disodium hexahydrate) is our first FDA-approved product and is the only approved oral spleen tyrosine kinase (SYK) inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. The product is also commercially available in Europe and the United Kingdom (UK) (as TAVLESSE), and in Japan, the Republic of Korea (Korea), Canada and Israel (as TAVALISSE) for the treatment of chronic ITP in adult patients.

REZLIDHIA ® (olutasidenib) is our second FDA-approved product and indicated for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. W e in-licensed REZLIDHIA from Forma Therapeutics, Inc., now Novo Nordisk (Forma), with exclusive, worldwide rights for its development, manufacturing and commercialization, pursuant to a license and transition services agreement entered in July 2022.

Revenue and profit, by fiscal year.

More on RIGL.

• Rigel Pharmaceuticals Inc summary
• Rigel Pharmaceuticals Inc financial statements
• Rigel Pharmaceuticals Inc key metrics
• Rigel Pharmaceuticals Inc health scores and style box
• Rigel Pharmaceuticals Inc earnings
• Rigel Pharmaceuticals Inc dividends
• Rigel Pharmaceuticals Inc valuation
• Rigel Pharmaceuticals Inc ownership and insiders
• Rigel Pharmaceuticals Inc peers

Figures from Rigel Pharmaceuticals Inc's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.